LOG IN
SIGN UP
MARKET
ORGO
ORGO
Organogenesis Hldgs Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
4.850
+0.040
+0.83%
Opening 11:10 08/11 EDT
OPEN
4.900
PREV CLOSE
4.810
HIGH
4.919
LOW
4.730
VOLUME
438.70K
TURNOVER
1.31M
52 WEEK HIGH
17.50
52 WEEK LOW
4.620
MARKET CAP
626.28M
P/E (TTM)
7.62
1D
5D
1M
3M
1Y
5Y
Sector Update: Health Care Stocks Set to Finish Moderately Higher
Sector Update: Health Care Stocks Set to Finish Moderately Higher
MT Newswires · 23h ago
Organogenesis' Q2 Operating Income Fell 50%, Lowers Annual Guidance
Organogenesis Holdings Inc's (NASDAQ: ORGO) Q2 FY22 sales reached $121.4 million, down 1% Y/Y, slightly ahead of the consensus of $120.90 million. The decrease was driven by a 35% decrease in Surgical & Sports Medicine products, partially offset by a 2% in...
Benzinga · 1d ago
Sector Update: Health Care Stocks Carried Higher with Broader Markets
Sector Update: Health Care Stocks Carried Higher with Broader Markets
MT Newswires · 1d ago
--Oppenheimer Downgrades Organogenesis Holdings to Perform From Outperform, Removes $14 Price Target
--Oppenheimer Downgrades Organogenesis Holdings to Perform From Outperform, Removes $14 Price Target
MT Newswires · 1d ago
Organogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates
Organogenesis (ORGO) delivered earnings and revenue surprises of 12.50% and 0.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
Recap: Organogenesis Q2 Earnings
Organogenesis Hldgs (NASDAQ:ORGO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 1d ago
CORRECTION: Organogenesis Holdings Q2 Adj. EPS $0.09 Beats $0.08 Estimate, Sales $121.40M Beat $120.90M Estimate
Organogenesis Holdings (NASDAQ:ORGO) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.08 by 12.5 percent. This is a 40 percent decrease over earnings of $0.15 per share from
Benzinga · 1d ago
Organogenesis Holdings reports Q2 earnings; narrows FY22 guidance
Organogenesis Holdings press release (<span class="ticker-hover-w...
Seekingalpha · 1d ago
No Data
Learn about the latest financial forecast of ORGO. Analyze the recent business situations of Organogenesis Hldgs Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 2 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
50.00%Strong Buy
0.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ORGO stock price target is 13.00 with a high estimate of 13.00 and a low estimate of 13.00.
Current 4.850
EPS
Actual
Estimate
0.100.200.290.39
- 0
Institutional Holdings
Institutions: 169
Institutional Holdings: 60.72M
% Owned: 47.03%
Shares Outstanding: 129.13M
TypeInstitutionsShares
Increased
66
7.97M
New
27
1.68M
Decreased
44
6.15M
Sold Out
25
1.17M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
-0.58%
Pharmaceuticals & Medical Research
-0.16%
Key Executives
Chairman/Director
Alan Ades
President/Chief Executive Officer/Director
Gary Gillheeney
Chief Financial Officer
David Francisco
Chief Operating Officer
Patrick Bilbo
Vice President/General Counsel
Lori Freedman
Vice President
Antonio Montecalvo
Other
Brian Grow
Director
Robert Ades
Director
David Erani
Director
Glenn Nussdorf
Independent Director
Michael Driscoll
Independent Director
Prathyusha Duraibabu
Independent Director
Jon Giacomin
Independent Director
Michele Korfin
Independent Director
Arthur Leibowitz
Independent Director
Gilberto Quintero
No Data
No Data
About ORGO
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier for a variety of wound types, and the Affinity, Novachor and NuShield wound coverings to address a variety of wound sizes and types. Sports medicine products include NuShield for surgical application in soft tissue repairs, and Affinity, Novachor and PuraPly AM for management of open wounds in the surgical setting. It offers its products to a range of healthcare customers, including hospitals, wound care centers and physician offices.
Webull offers kinds of Organogenesis Holdings Inc stock information, including NASDAQ:ORGO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORGO stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ORGO stock methods without spending real money on the virtual paper trading platform.